At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 26 enrolled
Drug / intervention
nivolumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)
In Brief
A Phase 3 clinical trial evaluating nivolumab, ipilimumab, and 1 other intervention for Cancer, Hepatocellular. Completed, enrolled 26 participants across 107 sites in 19 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Hepatocellular
CountriesAustralia, Austria, Belgium, Canada, China, Czechia, France, Germany, Hong Kong, Italy, Japan, Poland, Puerto Rico, Russia, Singapore, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartSep 2020
Primary CompletionDec 2023
TodayJul 2026
First PostedApr 9, 2020
Enrollment StartSep 14, 2020
Primary CompletionDec 12, 2023
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6.2 years ago
Interventions
nivolumabdrug
Specified dose on specified days
ipilimumabdrug
Specified dose on specified days
TACEprocedure
TACE (Trans-arterial ChemoEmbolization)